OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation
| Image |  |
|---|---|
| Description | scientific article published on 22 February 2020 |
| Author/s | |
| Publication date | February 22, 2020 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |